Regional practice norms for the care of childhood cancer survivors at risk for cardiomyopathy: A Delphi study. Issue 9 (31st May 2019)

• Record Type: Journal Article
• Authors: Kenney, Lisa B.; Ames, Bethany; Margossian, Renee; Moss, Kerry; Michaud, Alexis L.; Williams, David N.; Nohria, Anju
• Is Part Of: Pediatric blood & cancer. Volume 66:Issue 9(2019)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2019-05-31
• Subjects: cardiomyopathy -- cardiotoxicity -- childhood cancer -- Delphi method -- long‐term complications -- survivorship; Tumors in children -- Periodicals; Blood -- Diseases -- Periodicals; Cancer in children -- Periodicals; 618.92
• DOI: 10.1002/pbc.27868
• Languages: English
• ISSNs: 1545-5009

Abstract

Abstract: Background: Treatment‐associated cardiomyopathy is a leading cause of morbidity and mortality for childhood cancer survivors (CCS). As evidence is not available to guide the management of CCS at risk for cardiomyopathy, we aim to describe the collective opinion of regional experts for the care of these patients using a consensus‐based Delphi methodology. Procedure: Nineteen physicians from the New England region who care for CCS treated with cardiotoxic therapy (anthracyclines, thoracic radiation) participated in a Delphi panel querying their management approach, using three rounds of anonymous questionnaires formatted as five clinical scenarios. Consensus ≥ 89% agreement. Results: The response rate was 100% for the first round and 95% for subsequent rounds. Panelists reached consensus on screening asymptomatic CCS with serial echocardiograms (94%) and electrocardiograms (89%), with some disagreement on frequency during pregnancy (83%). All panelists agreed with exercise promotion, with no restrictions on weight training. Consensus was reached on indications for referrals; cardiology for asymptomatic left ventricular dysfunction (ALVD) (100%) and maternal–fetal medicine for pregnancy (94%). In the scenario of ALVD, there was disagreement on the benefit of additional cardiac testing (50% cardiologists recommended cardiac MRI), and although all panelists endorsed treating with angiotension‐converting enzyme (ACE) inhibitors, most adult cardiologists (75%) also recommended therapy with beta blockers, compared with none of the pediatric cardiologists or primary‐care physicians. Conclusions: Despite a lack of evidence to guide the management of CCS at risk for cardiomyopathy, a panel of regional physicians reached consensus on managing most clinical scenarios. A controversial area requiring further study is the medical management of ALVD.